# Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Canonical URL: https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-appointment-of-richard-n-kender-as-executive-chair-and-interim-ceo-provides-business-updates
Ticker: MCRB
Company: Seres Therapeutics
Source: Seres Therapeutics
Published: 2026-03-02 21:05 EST
Original Source URL: https://ir.serestherapeutics.com
## Summary

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155

## Article Body
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155
## Recent Company News
- 2026-07-08 11:00 EST — [Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-early-clinical-data-showing-potential-for-ser-155-i-55053722) — Source: Seres Therapeutics
- 2026-06-25 11:00 EST — [Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investig-6fc7afb2) — Source: Seres Therapeutics
- 2026-06-05 11:00 EST — [Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-two-transactions-to-strengthen-balance-sheet-reduce-c0cf0416) — Source: Seres Therapeutics
- 2026-05-12 11:00 EST — [Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Seres Therapeutics
- 2026-05-05 11:00 EST — [Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Seres Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)